Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Free Cash Flow (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Free Cash Flow for 5 consecutive years, with -$12.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 28.95% to -$12.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$51.8 million through Dec 2025, up 30.25% year-over-year, with the annual reading at -$51.8 million for FY2025, 30.25% up from the prior year.
  • Free Cash Flow hit -$12.0 million in Q4 2025 for Kezar Life Sciences, down from -$9.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$8.4 million in Q1 2021 to a low of -$22.9 million in Q1 2024.
  • Historically, Free Cash Flow has averaged -$15.6 million across 5 years, with a median of -$15.8 million in 2022.
  • Biggest five-year swings in Free Cash Flow: crashed 65.95% in 2023 and later skyrocketed 43.87% in 2025.
  • Year by year, Free Cash Flow stood at -$11.5 million in 2021, then tumbled by 38.14% to -$15.8 million in 2022, then decreased by 19.76% to -$19.0 million in 2023, then increased by 11.3% to -$16.8 million in 2024, then increased by 28.95% to -$12.0 million in 2025.
  • Business Quant data shows Free Cash Flow for KZR at -$12.0 million in Q4 2025, -$9.8 million in Q3 2025, and -$12.8 million in Q2 2025.